← Back to headlines
Puma Biotechnology Forecasts NERLYNX Revenue and Plans Clinical Trials
Puma Biotechnology forecasts NERLYNX net product revenue of $202 million to $206 million in 2026, while also planning alisertib dose escalation and a new Lung2 trial.
8 May, 13:47 — 8 May, 13:47
Sources
Showing 1 of 1 sources
